Nika Pharmaceuticals, INC 10-Q quarterly reports

Nika Pharmaceuticals, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing net losses and a significant accumulated deficit, raising substantial doubt about its ability to continue as a going concern.

Nika Pharmaceuticals, Inc. reported its Q1 2026 financial results, detailing a net loss and ongoing reliance on related party financing, while also highlighting strategic agreements and operational developments.

Nika Pharmaceuticals reports reduced net losses and cash burn in Q3 2025, alongside ongoing pharmaceutical factory development and significant related party transactions.

Nika Pharmaceuticals, Inc. reported reduced net losses and increased cash for Q2 2025, but faces going concern doubts and internal control deficiencies.

Nika Pharmaceuticals reports a reduced net loss for the quarter ended March 31, 2025, as it continues to execute its strategic business plan.

Nika Pharmaceuticals reported its Q3 2024 results, showing a net loss and ongoing efforts to establish its pharmaceutical manufacturing capabilities.

Nika Pharmaceuticals' Q2 2024 report reveals a period of significant activity including mergers, acquisitions, and strategic shifts, alongside a net loss and ongoing going concern challenges.

Nika Pharmaceuticals reported its first revenue of $156 in Q2 2024, while also undergoing significant restructuring and expansion, including mergers and acquisitions.

Nika Pharmaceuticals reported a net loss for Q1 2024, completed a merger with Nika BioTechnology, and expanded its operations through acquisitions and agreements.